It is quite well known that proton-pump inhibitors (PPI) im- pair intestinal magnesium (Mg) absorption and can lead to. Mg depletion (and hypomagnesemia) ...
Global Kidney Academy
www.gkaonlineacademy.com/karger
Hypomagnesemia in Hemodialysis Patients: Role of Proton Pump Inhibitors M. Alhosaini, J.S. Walter, S. Singh, R.S. Dieter, A. Hsieh, D.J. Leehey Am J Nephrol 2014;39:204–209 DOI: 10.1159/000360011
Commentary By Professor Richard Glassock It seems that moderate hypomagnesemia is more prevalent among PPI users when dialysis is carried out at a standard dialysate Mg concentration (0.75–1.0 mEq/l). This study did not address the adverse consequences of such ‘PPI-induced’ hypomagnesemia, but theoretically it might contribute to enhancement of cardiovascular morbidity (particularly sudden cardiac death), so these agents should be used with caution and with appropriate monitoring of serum Mg levels, especially in subjects at increased risk of ventricular arrhythmias (e.g. severe left ventricular hypertrophy). The interactions of ‘PPI-induced’ hypomagnesemia and fluctuations of serum potassium concentrations during dialysis deserve further study.
Follow and participate in the discussion of this article
KI14663
It is quite well known that proton-pump inhibitors (PPI) impair intestinal magnesium (Mg) absorption and can lead to Mg depletion (and hypomagnesemia) when dietary intake of Mg is reduced and/or renal/extra- renal losses of Mg are increased. Hypomagnesemia can be associated with increased risk of cardiovascular morbidity and mortality. Alhosaini and co-workers have retrospectively assessed the occurrence of hypomagnesemia (serum Mg levels of 2.0 mEq/l, whereas 37% of those not using a PPI had serum Mg levels of >2.0 mEq/l. Severe hypomagnesemia (serum Mg
